The four mouse IgG isotypes differ extensively in bactericidal and opsonophagocytic activity when reacting with the P1.16 epitope on the outer membrane PorA protein of Neisseria meningitidis

Scandinavian Journal of Immunology

Volumn 59, Issue 1, 2004, Pages 34-39

  Michaelsen, T E ^a,b   Kolberg, J ^a   Aase, A ^a   Herstad, T K ^a   Hoiby E A ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM DERIVATIVE; BACTERIAL PROTEIN; COMPLEMENT; EPITOPE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; ISOPROTEIN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PORIN A; UNCLASSIFIED DRUG;

ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; ELUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; NORMAL HUMAN; OUTER MEMBRANE; PHAGOCYTOSIS; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SERUM BACTERICIDAL ACTIVITY;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; COMPLEMENT SYSTEM PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FLOW CYTOMETRY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; MICE; NEISSERIA MENINGITIDIS; OPSONIN PROTEINS; PHAGOCYTOSIS; PORINS;

EID: 0442291929     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0300-9475.2004.01362.x     Document Type: Article

References (38)

1. Armand J, Arminjon F, Mynard MC, Lafaix C. Tetravalent meningococcal polysaccharide vaccine groups A, C, Y, W 135: clinical and serological evaluation. J Biol Stand 1982;10:335-9.
2. Jodar L, Feavers IM, Salisbury D, Granoff DM. Development of vaccines against meningococcal disease. Lancet 2002;359:1499-508.
3. Bitter-Suermann D, Roth J. Monoclonal antibodies to polysialic acid reveal epitope sharing between invasive pathogenic bacteria, differentiating cells and tumor cells. Immunol Res 1987;6:225-37.
4. Fredriksen JH, Rosenqvist E, Wedege E et al. Production, characterization and control of MenB-vaccine 'Folkehelsa': an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Annals 1991;14:67-79.
5. Bjune G, Hoiby EA, Gronnesby JK et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991;338:1093-6.
6. Frasch CE, Parkes L, McNelis RM, Gotschlich EC. Protection against group B meningococcal disease. I. Comparison of group-specific and type-specific protection in the chick embryo model. J Exp Med 1976;144:319-29.
7. Goldschneider I, Gorschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969;129:1307-26.
8. Halstensen A, Haneberg B, Froholm LO, Lehmann V, Frasch CE, Solberg CO. Human opsonins to meningococci after vaccination. Infect Immun 1984;46:673-6.
9. Ross SC, Rosenthal PJ, Betberich HM, Densen P. Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals. J Infect Dis 1987;155:1266-75.
10. Aase A, Bjune G, Hoiby EA, Rosenqvist E, Pedersen AK, Michaelsen TE. Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a setogtoup B outer membrane vesicle vaccine. Infect Immun 1995;63:3531-6.
11. Ey PL, Russell-Jones GJ, Jenkin CR. Isotypes of mouse IgG - I. Evidence for 'non-complement-fixing' IgG1 antibodies and characterization of their capacity to interfere with IgG2 sensitization of target red blood cells for lysis by complement. Mol Immunol 1980;17:699-710.
12. Germann T, Bongartz M, Dlugonska H et al. Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. Eur J Immunol 1995;25:823-9.
13. Ravetch JV. Fc receptors: rubor redux. Cell 1994;78:553-60.
14. Briles DE, Forman C, Hudak S, Claflin JL. The effects of subclass on the ability of anti-phosphocholine antibodies to protect mice from fatal infection with Streptococcus pneumoniae. J Mol Cell Immunol 1984;1:305-9.
15. Briles DE, Claflin JL, Schroer K, Forman C. Mouse IgG3 antibodies are highly protective against infection with Streptococcus pneumoniae. Nature 1981;294:88-90.
16. Schreiber JR, Cooper LJ, Diehn S et al. Variable region-identical monoclonal antibodies of different IgG subclass directed to Pseudomonas aeruginosa lipopolysaccharide O-specific side chain function differently. J Infect Dis 1993;167:221-6.
17. Yuan R, Casadevall A, Spira G, Scharff MD. Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. J Immunol 1995;154:1810-6.
18. Martin SL, Borrow R, van der LP, Dawson M, Fox AJ, Cartwright KA. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine 2000;18:2476-81.
19. van der Voort ER, van der LPBJ, George S, Tunnela O, van Dijken H et al. Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect Immun 1996;64:2745-51.
20. Michaelsen TE, Aase A, Kolberg J, Wedge E, Rosenqvist E. PorB3 outer membrane protein on Neisseria meningitidis is poorly accessible for antibody binding on live bacteria. Vaccine 2001;19:1526-33.
21. Wedege E, Bryn K, Froholm LO. Restoration of antibody binding to blotted meningococcal outer membrane proteins using various detergents. J Immunol Methods 1988;113:51-9.
22. Pullen GR, Fitzgerald MG, Hosking CS. Antibody avidity determination by ELISA using thiocyanate elution. J Immunol Methods 1986;86:83-7.
23. Rosenqvist E, Hoiby EA, Wedege E et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 1995;63:4642-52.
24. Aase A, Hoiby EA, Michaelsen TE. Opsonophagocytic and bactericidal activity mediated by purified IgG subclass antibodies after vaccination with the Norwegian group B meningococcal vaccine. Scand J Immunol 1998;47:388-96.
25. Michaelsen TE, Aase A. Antibody-induced opsonophagocytosis of serogroup B meningococci measured by flow cytometry. In: Pollard AJ, Maiden MCJ, eds. Meningococcal Vaccines. Methods and Protocols. Totowa: Humana, 2001, 331-7.
26. Warmerdam PA, van de Winkel JG, Vlug A, Westerdaal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol 1991;147:1338-43.
27. Boslego J, Garcia J, Cruz C et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15 : P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 1995;13:821-9.
28. Muller-Eberhard HJ. The membrane attack complex of complement. Annu Rev Immunol 1986;4:503-28.
29. Poolman JT, Timmermans HA, Hopman CT et al. Comparison of meningococcal outer membrane protein vaccines solubilized with detergent or C polysaccharide. Antonie Van Leeuwenhoek 1987;53:413-9.
30. van den Elsen JM, van Pomeren E, Poolman JT, Wilting J, Herron JN, Crommelin DJ. On the interaction between a bactericidal antibody and a PorA epitope of Neisseria meningitidis in outer membrane vesicles: a competitive fluorescence polarization immunoassay. Anal Biochem 1997;247:382-8.
31. Schlesinger Y, Granoff DM. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA 1992;267:1489-94.
32. McGuinness BT, Lambden PR, Heckels JE. Class 1 outer membrane protein of Neisseria meningitidis: epitope analysis of the antigenic diversity between strains, implications for subtype definition and molecular epidemiology. Mol Microbiol 1993;7:505-14.
33. Aase A, Michaelsen TE. Opsonophagocytic activity induced by chimeric antibodies of the four human IgG subclasses with or without help from complement. Scand J Immunol 1994;39:581-7.
34. Hulett MD, Hogarth PM. Molecular basis of Fc receptor function. Adv Immunol 1994;57:1-127.
35. Oishi K, Koles NL, Guelde G, Pollack M. Antibacterial and protective properties of monoclonal antibodies reactive with Escherichia coli O111 : B4 lipopolysaccharide: relation to antibody isotype and complement-fixing activity. J Infect Dis 1992;165:34-45.
36. Oi VT, Vuong TM, Hardy R et al. Correlation between segmental flexibility and effector function of antibodies. Nature 1984;307:136-40.
37. Michaelsen TE, Garred P, Aase A. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur J Immunol 1991;21:11-6.
38. Lucisano Valim YM, Lachmann PJ. The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin Exp Immunol 1991;84:1-8.